Literature DB >> 31526079

Glutamine synthetase facilitates cancer cells to recover from irradiation-induced G2/M arrest.

Yanni Peng1, Shujun Fu1,2, Wenfeng Hu1,2, Yanfang Qiu1, Lu Zhang1,2, Rong Tan1,2,3, Lun-Quan Sun1,2,3,4.   

Abstract

Resistance to radiation of cancer cells can be either intrinsic or acquired, leading to treatment failure. In response to DNA damage caused by IR, cancer cells are arrested in cell cycle showing limited proliferation and increased apoptosis. However, radiation-resistant cells are able to overcome the cell cycle block and proceed to proliferation, for which the detailed mechanism remains to be elucidated. In the present study, we showed that radioresistant cells exhibited a recoverable G2/M phase during prolonged cell cycle and manifested lower apoptosis rate and more colony formation. RNA-seq analysis revealed that glutamine synthetase (GS, GLUL) gene was highly expressed in radioresistant cancer cells in comparison with the parental cells, which was in accordance with the G2/M arrest after ionizing radiation. Knocking out of GS in radioresistant cells resulted in a delayed G2/M recovery and lowered proliferation rate after ionizing radiation treatment, which was accompanied with increased inhibitory phosphorylation of CDK1 at Y15 and downregulated Cdc25B, a dual specific phosphatase of CDK1. Moreover, there was an enhanced complex formation of CDK1 and Cyclin B1 when the cells were rescued by re-introducing GS. In vivo, knocking down of GS significantly sensitized CNE2-R xenografts to RT in mice. In this study, we demonstrate a novel role of glutamine synthetase independent of metabolic function in promoting recovery from G2/M arrest caused by ionizing radiation, thus, causing cancer cell resistance to radiotherapy.

Entities:  

Keywords:  CDK1; Cyclin B1; GS; cell cycle; radioresistance

Mesh:

Substances:

Year:  2019        PMID: 31526079      PMCID: PMC7012188          DOI: 10.1080/15384047.2019.1665394

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  35 in total

Review 1.  How does radiation kill cells?

Authors:  E C Jonathan; E J Bernhard; W G McKenna
Journal:  Curr Opin Chem Biol       Date:  1999-02       Impact factor: 8.822

2.  To arrest or not to G(2)-M Cell-cycle arrest : commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin. cancer res., 8: 3512-3519, 2002.

Authors:  Robert S DiPaola
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

Review 3.  Radiation and the cell cycle, revisited.

Authors:  George D Wilson
Journal:  Cancer Metastasis Rev       Date:  2004 Aug-Dec       Impact factor: 9.264

Review 4.  Targeting the checkpoint kinases: chemosensitization versus chemoprotection.

Authors:  Bin-Bing S Zhou; Jiri Bartek
Journal:  Nat Rev Cancer       Date:  2004-03       Impact factor: 60.716

Review 5.  Regulation of the cellular DNA double-strand break response.

Authors:  Kendra L Cann; Geoffrey G Hicks
Journal:  Biochem Cell Biol       Date:  2007-12       Impact factor: 3.626

6.  Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.

Authors:  G Lossaint; E Besnard; D Fisher; J Piette; V Dulić
Journal:  Oncogene       Date:  2011-05-02       Impact factor: 9.867

Review 7.  Nasopharyngeal carcinoma.

Authors:  William I Wei; Jonathan S T Sham
Journal:  Lancet       Date:  2005 Jun 11-17       Impact factor: 79.321

8.  The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).

Authors:  Yann Cormerais; Pierre André Massard; Milica Vucetic; Sandy Giuliano; Eric Tambutté; Jerome Durivault; Valérie Vial; Hitoshi Endou; Michael F Wempe; Scott K Parks; Jacques Pouyssegur
Journal:  J Biol Chem       Date:  2018-01-11       Impact factor: 5.157

9.  Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma.

Authors:  Saverio Tardito; Anaïs Oudin; Shafiq U Ahmed; Fred Fack; Olivier Keunen; Liang Zheng; Hrvoje Miletic; Per Øystein Sakariassen; Adam Weinstock; Allon Wagner; Susan L Lindsay; Andreas K Hock; Susan C Barnett; Eytan Ruppin; Svein Harald Mørkve; Morten Lund-Johansen; Anthony J Chalmers; Rolf Bjerkvig; Simone P Niclou; Eyal Gottlieb
Journal:  Nat Cell Biol       Date:  2015-11-23       Impact factor: 28.824

10.  ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.

Authors:  M van Geldermalsen; Q Wang; R Nagarajah; A D Marshall; A Thoeng; D Gao; W Ritchie; Y Feng; C G Bailey; N Deng; K Harvey; J M Beith; C I Selinger; S A O'Toole; J E J Rasko; J Holst
Journal:  Oncogene       Date:  2015-10-12       Impact factor: 9.867

View more
  5 in total

1.  DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.

Authors:  Rui-Xue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-05-01

Review 2.  Glutamine Synthetase as a Therapeutic Target for Cancer Treatment.

Authors:  Go Woon Kim; Dong Hoon Lee; Yu Hyun Jeon; Jung Yoo; So Yeon Kim; Sang Wu Lee; Ha Young Cho; So Hee Kwon
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

Review 3.  Overcoming Radiation Resistance in Gliomas by Targeting Metabolism and DNA Repair Pathways.

Authors:  Wei Meng; Joshua D Palmer; Michael Siedow; Saikh Jaharul Haque; Arnab Chakravarti
Journal:  Int J Mol Sci       Date:  2022-02-17       Impact factor: 5.923

4.  Mechanism-Based Sonodynamic-Chemo Combinations against Triple-Negative Breast Cancer.

Authors:  Xiaolan Feng; Chen Wu; Wenhao Yang; Jiayi Wu; Pan Wang
Journal:  Int J Mol Sci       Date:  2022-07-20       Impact factor: 6.208

5.  Metabolic pathways underlying GATA6 regulating Trastuzumab resistance in Gastric Cancer cells based on untargeted metabolomics.

Authors:  Jinxia Chang; Qiang Wang; Anup Bhetuwal; Wenhu Liu
Journal:  Int J Med Sci       Date:  2020-10-23       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.